Articles related to ANTIBIOTICS

A randomized noninferiority trial found that oral fosfomycin matched continued intravenous therapy in stabilized patients with ESBL complicated UTIs after 3 to 7 days of initial IV treatment.

The FDA approved cefepime-zidebactam (Zaynich) for complicated UTI and pyelonephritis caused by susceptible gram-negative organisms. Approval followed phase 3 trial data showing higher rates of symptom and microbiologic resolution compared with meropenem in hospitalized adults.

Cotrimoxazole was associated with nearly twice the adverse event rate of fluoroquinolones in a retrospective study of 228 hospitalized men aged 75 or older with urinary tract infections, with acute kidney injury onset occurring at a median of six days post-initiation.

Given that human-targeted drugs are often taken continuously throughout life, not for short periods, which is the case for antibiotics, the physiological effects can be even more profound.

Between 2019 and 2023, NDM-CRE infections, including pneumonia, bloodstream infections, urinary tract infections, and wound infections, surged by more than 460 percent in the United States.

Compared to those co-prescribed azithromycin, patients receiving clarithromycin had a significantly higher risk of hyperkalemia and AKI. The risk of hyperkalemia increased as kidney function declined.